{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:40:36Z","timestamp":1760823636740,"version":"build-2065373602"},"reference-count":29,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"unspecified","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence in Melanoma grant","award":["1135285"],"award-info":[{"award-number":["1135285"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,12,5]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The benefits of patient-reported feedback, using questionnaires that allow patients to report how they feel and function without any interpretation from healthcare professionals, are well established. However, patient-reported outcomes measures (PROMs) are not routinely collected in patients with melanoma in Australia. The aim of this study is to evaluate the feasibility and acceptability of implementing electronic PROMs (ePROMs) into routine care from the perspectives of patients with stage III melanoma and their treating clinical team.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>A minimum of 50 patients and 5 clinicians will be recruited to this prospective, longitudinal pilot study (ePROMs-MELanoma). The study uses a mixed-methods approach (quantitative PROMs questionnaires and end-of-study surveys with qualitative interviews) and commenced in May 2021 in surgical and medical melanoma clinics at two sites in metropolitan Sydney, Australia. The primary outcomes are measures of feasibility and acceptability, comprising descriptive questionnaire completion statistics, and proportion of patients who reported that these PROMs were easy to complete and measured items they considered important. Clinician and clinic staff views will be canvassed on the appropriateness of these PROMs for their patients, change in referral practice and uptake and incorporation into routine practice. Secondary aims include measurement of improvements in patients\u2019 emotional and physical health and well-being, and utility of real-time data capture and clinician feedback. All participants will complete the Distress Thermometer and EQ-5D-5L questionnaires in the clinic using a tablet computer at baseline and two to three subsequent follow-up appointments. Participants who report a score of 4 or higher on the Distress Thermometer will be triaged to complete an additional three questionnaires: the QLQ-C30, Depression, Anxiety and Stress Scale and Melanoma Concerns Questionnaire-28. Results will be generated in real time; patients with psychosocial distress or poor quality of life will discuss possible referral to appropriate allied health services with their clinician. Thematic analysis of interviews will be conducted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>Ethics approval obtained from St Vincent\u2019s Hospital Human Research Ethics Committee on 19 September 2019 (2019\/ETH10558), with amendments approved on 8 June 2022. Patient consent is obtained electronically prior to questionnaire commencement. Dissemination strategies will include publication in peer-reviewed journals and presentation at international conferences, tailored presentations for clinical societies and government bodies, organisational reporting through multidisciplinary meetings and research symposia for local clinicians and clinic staff, and more informal, lay reports and presentations for consumer melanoma representative bodies and patient participants and their families.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>ACTRN12620001149954.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-066852","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T09:57:21Z","timestamp":1671530241000},"page":"e066852","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Embedding electronic patient-reported outcome measures into routine care for patients with stage III MELanoma (ePROMs-MEL): protocol for a prospective, longitudinal, mixed-methods pilot study"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-0857","authenticated-orcid":false,"given":"Kathy","family":"Dempsey","sequence":"first","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, New South Wales, Australia"},{"name":"Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn","family":"Saw","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Bartula","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serigne","family":"Lo","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Lawn","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Pennington","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Spillane","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Boyle","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Skye","family":"Dong","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mbathio","family":"Dieng","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, New South Wales, Australia"},{"name":"Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Milne","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Seaman","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Saks","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Lai-Kwon","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0823-3218","authenticated-orcid":false,"given":"Jake Robert","family":"Thompson","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael","family":"Morton","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, New South Wales, Australia"},{"name":"Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"2025101813592279000_12.12.e066852.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2015.10.027"},{"key":"2025101813592279000_12.12.e066852.2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2018.07.008","article-title":"Patient reported outcomes in evaluation of chemotherapy toxicity in women with gynecologic malignancies: a pilot study","volume":"150","author":"Webster","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2025101813592279000_12.12.e066852.3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2017.09.011","article-title":"Patient-reported outcome measures (PROMs) in the management of lung cancer: a systematic review","volume":"113","author":"Bouazza","year":"2017","journal-title":"Lung Cancer"},{"key":"2025101813592279000_12.12.e066852.4","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-019-0538-9","article-title":"Proactive use of PROMs in ovarian cancer survivors: a systematic review","volume":"12","author":"Kargo","year":"2019","journal-title":"J Ovarian Res"},{"key":"2025101813592279000_12.12.e066852.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7156"},{"key":"2025101813592279000_12.12.e066852.6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.1998.16.4.1594","article-title":"Oncologists' recognition of depression in their patients with cancer","volume":"16","author":"Passik","year":"1998","journal-title":"J Clin Oncol"},{"key":"2025101813592279000_12.12.e066852.7","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1724"},{"key":"2025101813592279000_12.12.e066852.8","unstructured":"National Comprehensive Cancer Network (NCCN) . NCCN clinical practice guidelines in oncology. distress management. V2, 2020. Available: NCCN.org [Accessed 11 Mar 2020]."},{"key":"2025101813592279000_12.12.e066852.9","doi-asserted-by":"publisher","DOI":"10.1002\/pon.3920"},{"key":"2025101813592279000_12.12.e066852.10","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1200\/JCO.2016.68.2278","article-title":"Psychoeducational intervention to reduce fear of cancer recurrence in people at high risk of developing another primary melanoma: results of a randomized controlled trial","volume":"34","author":"Dieng","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025101813592279000_12.12.e066852.11","first-page":"779","article-title":"Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma","volume":"23","author":"Stamataki","year":"2015","journal-title":"Support Care Cancer"},{"key":"2025101813592279000_12.12.e066852.12","first-page":"3489","article-title":"Supportive care and unmet needs in patients with melanoma: a mixed-methods systematic review","volume":"28","author":"Fu","year":"2020","journal-title":"Support Care Cancer"},{"key":"2025101813592279000_12.12.e066852.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2011.11.005"},{"key":"2025101813592279000_12.12.e066852.14","unstructured":"Cancer Institute NSW . Patient-Reported measures (PRMs). Available: https:\/\/www.cancer.nsw.gov.au\/patient-reported-measures [Accessed 12 May 2020]."},{"key":"2025101813592279000_12.12.e066852.15","unstructured":"Australian Commission on Safety and Quality in Health Care . Evidence on the use of PROMs in clinical practice, clinical research, quality improvement and policy development."},{"key":"2025101813592279000_12.12.e066852.16","first-page":"249","article-title":"A cross-sectional audit of current practices and areas for improvement of distress screening and management in Australian cancer services: is there a will and a way to improve?","volume":"28","author":"Fradgley","year":"2020","journal-title":"Support Care Cancer"},{"key":"2025101813592279000_12.12.e066852.17","unstructured":"Insight Economics, Melanoma Institute Australia and Melanoma Patients Australia . State of the nation. A report into melanoma \u2013 a national health priority.Final report. Sydney, 2022."},{"key":"2025101813592279000_12.12.e066852.18","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/pon.4290","article-title":"Systematic review of psychosocial outcomes for patients with advanced melanoma","volume":"26","author":"Dunn","year":"2017","journal-title":"Psychooncology"},{"key":"2025101813592279000_12.12.e066852.19","unstructured":"The National Comprehensive Cancer Network (NCCN\u00ae) . NCCN distress thermometer and problem list for patients. version 2; 2018 [Accessed 23 Feb 2018]."},{"key":"2025101813592279000_12.12.e066852.20","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025101813592279000_12.12.e066852.21","doi-asserted-by":"crossref","unstructured":"Winstanley J , Boyle F , Young T . Melanoma Concerns Questionnaire\u00a9 [MCQ-28] Version 1; 2020 [Accessed 31 Jun 2020].","DOI":"10.1037\/t88114-000"},{"key":"2025101813592279000_12.12.e066852.22","doi-asserted-by":"crossref","unstructured":"Lovibond SH , Lovibond PF . Manual for the depression anxiety stress scales. 2nd ed. Sydney: Psychology Foundation, 1995.","DOI":"10.1037\/t01004-000"},{"key":"2025101813592279000_12.12.e066852.23","unstructured":"European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group . Quality of life Questionnaire-Cancer 30 (QLQ-C30). version 3.0."},{"key":"2025101813592279000_12.12.e066852.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.05.008"},{"key":"2025101813592279000_12.12.e066852.25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2018.09.005","article-title":"Interpreting European organisation for research and treatment for cancer quality of life questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma","volume":"104","author":"Musoro","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025101813592279000_12.12.e066852.26","doi-asserted-by":"publisher","DOI":"10.1007\/s10488-010-0319-7"},{"key":"2025101813592279000_12.12.e066852.27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/resp.12217","article-title":"Models for the analysis of repeated continuous outcome measures in clinical trials","volume":"19","author":"De Livera","year":"2014","journal-title":"Respirology"},{"key":"2025101813592279000_12.12.e066852.28","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-13-117","article-title":"Using the framework method for the analysis of qualitative data in multi-disciplinary health research","volume":"13","author":"Gale","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"2025101813592279000_12.12.e066852.29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.21903"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-066852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:59:34Z","timestamp":1760821174000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-066852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,20]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/bmjopen-2022-066852"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-066852","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}